Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Microtubule Associated inhibitor
Epothilone A acts by stabilising microtubule formation at the taxol binding site and causes cell cycle arrest at the G2/M transition, leading to cytotoxicity. -
Microtubule Inhibitor
NPI-2358 is a synthetic analog of NPI-2350, a natural product isolated from Aspergillus sp., which depolymerizes microtubules in A549 human lung carcinoma cells. -
Tubulin inhibitor
Vincristine is a mitotic inhibitor, and is used in cancer chemotherapy. -
Microtubule Associated inhibitor
Vinflunine Tartrate is a tartrate salt of vinflunine that destabilizes microtubules with an IC50 of 18.8 nM and interferes with the dynamics of microtubules during cell division. -
tubulin polymerisation inhibitor
Lexibulin 2Hcl (CYT-997 2Hcl) is a potent tubulin polymerisation inhibitor with IC50 of 10-100 nM in cancer cell lines; with potent cytotoxic and vascular disrupting activity in vitro and in vivo. -
auristatin microtubule inhibitor
PF-06380101 (Aur0101), an auristatin microtubule inhibitor, is a cytotoxic Dolastatin 10 analogue. -
microtubule assembly and microtubule dynamics inhibitor
Tasidotin hydrochloride is a peptide analog of the antimitotic depsipeptide dolastatin 15, as an inhibitor of microtubule assembly and microtubule dynamics. -
bovine tubulin oxidation inhibitor
Takeda103A is a potent GRK2-dependent bovine tubulin oxidation inhibitor. -
inhibitor of tubulin polymerization
4-Oxo-4-HPR is an inhibitor of tubulin polymerization, inducing marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. It is also a fenretinide metabolite. -
Tubulin Inhibitor
Demecolcine is a potent tubulin inhibitor that effectively disrupts microtubule polymerization, exhibiting an IC50 value of 2.4 μM. By binding to tubulin dimers, Demecolcine exerts anti-mitotic effects, hindering cellular division. This compound is primarily utilized in research related to inflammatory disorders and various cancer pathways, making it valuable for studies focused on cell cycle regulation and targeted therapies. -
Microtubule Acetylation Inhibitor
GM-90257 is a potent microtubule acetylation inhibitor that directly binds to α-tubulin. By preventing the recruitment of α-tubulin acetyltransferase 1 (αTAT1) to the K40 residue, GM-90257 disrupts microtubule dynamics, leading to apoptotic cell death. It downregulates Bcl-2 and activates key apoptotic pathways, including JNK and PARP. This compound demonstrates significant anticancer activity in breast cancer models, making it a valuable tool for research in cancer therapeutics and microtubule biology. -
Microtubule Inhibitor
MPT0B214 is a potent microtubule inhibitor that targets the colchicine binding site of tubulin, effectively preventing tubulin polymerization. This compound induces apoptosis via a mitochondrial/caspase 9 dependent pathway and exhibits significant cytotoxic effects across a range of human tumor cell lines. MPT0B214 is suitable for applications in cancer research, allowing for further exploration of microtubule dynamics and therapeutic strategies. -
Tubulin Polymerization Inhibitor
Trilexium is a potent tubulin polymerization inhibitor that effectively disrupts microtubule integrity. This compound promotes the expression of p21 protein and triggers apoptotic pathways, demonstrating significant anti-cancer activities across various cell lines. Trilexium holds promise for research applications focused on cancer biology and novel therapeutic strategies targeting microtubule dynamics. -
Tubulin Inhibitor
Tubulin polymerization-IN-68 is a potent tubulin inhibitor that disrupts tubulin polymerization, thereby destabilizing the microtubule network within cells. This compound induces apoptosis by upregulating PARP-1 and caspase-3 expression, showcasing significant anticancer properties. Tubulin polymerization-IN-68 demonstrates effective inhibition of HepG2 cells with an IC50 of 93 nM and substantially reduces the growth of HepG2 xenograft tumors in nude mice when administered orally, making it a valuable tool for cancer research. -
Tubulin Inhibitor
STK899704 is a potent tubulin polymerization inhibitor that demonstrates broad-spectrum antitumor activity across various cancer cell lines, with IC50 values between 0.2 and 1.0 μM. By disrupting mitotic spindle formation, STK899704 induces G2/M phase cell cycle arrest and decreases cell migration in HT29 cells through the FAK-MEK-ERK signaling axis, leading to reduced expression and activity of MMP-2 and MMP-9. This compound activates caspases 3, 7, 8, and 9, resulting in PARP cleavage and subsequent apoptosis, alongside triggering cellular senescence via the p53 pathway. STK899704 is applicable in research focusing on skin cancer, lung cancer, colon cancer, and other malignancies. -
Tubulin Polymerization Inhibitor
SB-216 is a tubulin polymerization inhibitor that penetrates the blood-brain barrier. It demonstrates significant antitumor activity by inhibiting tumor cell proliferation and migration, as well as inducing apoptosis and cell cycle arrest. With favorable in vivo metabolic stability and low toxicity, SB-216 is suitable for research applications focused on various tumors, including melanoma, although its oral bioavailability is limited. -
Tubulin Polymerization Inhibitor
MPT0B014 is a potent tubulin polymerization inhibitor that disrupts microtubule dynamics. This compound has been shown to induce apoptosis in cancer cells, making it a valuable tool for studying cancer biology and therapeutic interventions. MPT0B014 is suitable for research focused on cancer treatment strategies and cellular response to microtubule-targeting agents. -
Tubulin inhibitor
Tubulin inhibitor 11 is a potent inhibitor of tubulin that acts by targeting the colchicine binding site on tubulin. It effectively inhibits tubulin polymerization, resulting in mitotic blockade and the induction of apoptosis. This compound is a valuable tool for research applications investigating cell division, cancer biology, and the mechanisms of drug resistance. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-56 is a potent inhibitor of tubulin polymerization that targets the colchicine binding site. This indazole derivative effectively induces cell cycle arrest and promotes cellular apoptosis. Additionally, Tubulin polymerization-IN-56 reduces cell migration, resulting in significant inhibition of tumor growth in vivo and demonstrating its potential for cancer research applications. -
Tubulin Polymerization Inhibitor
Thiocolchicine is a tubulin polymerization inhibitor that exhibits enhanced biological properties compared to its parent compound, colchicine. With an IC50 of 2.5 µM, it competitively binds to tubulin with a Ki of 0.7 µM, effectively disrupting microtubule dynamics and inducing cell apoptosis. Thiocolchicine serves as a valuable cytotoxin in antibody-drug conjugate (ADC) technology, making it an important reagent for cancer research and therapeutic development. -
Microtubulin polymerization Inhibitor
MY-1442 is a microtubulin polymerization inhibitor that functions by targeting colchicine binding sites on tubulin. This compound exhibits significant anticancer activity, effectively inducing apoptosis in MGC-803 cells. Additionally, MY-1442 has been shown to inhibit cell migration, making it a valuable reagent for research applications in cancer biology and cell motility studies. -
Tubulin Inhibitor
FC-116 is a potent tubulin inhibitor that disrupts microtubule dynamics, leading to the inhibition of colorectal cancer (CRC) cell proliferation. It demonstrates significant activity with IC50 values of 4.52 nM in HCT116 cells and 18.69 nM in CT26 cells. By inducing endoplasmic reticulum stress and generating excess reactive oxygen species (ROS), FC-116 promotes mitochondrial damage and apoptosis in CRC cells. This compound also exhibits substantial anti-tumor effects in vivo, making it a valuable reagent for colorectal cancer research. -
Tubulin Inhibitor
Taltobulin trifluoroacetate is a potent tubulin inhibitor that targets microtubule dynamics. This synthetic analogue of hemiasterlin effectively inhibits the polymerization of purified tubulin, leading to disrupted microtubule organization within cells. Taltobulin trifluoroacetate induces mitotic arrest and apoptosis, making it a valuable compound for research in cancer biology and studies focused on overcoming P-glycoprotein-mediated drug resistance. -
IDO/Tubulin Inhibitor
IDO/Tubulin-IN-2 is a potent inhibitor targeting both indoleamine 2,3-dioxygenase (IDO) and tubulin. This compound exhibits significant anticancer activity, demonstrated by its effect on various cell lines, including U87, HepG2, A549, HCT-116, and LO2, with IC50 values of 0.43, 0.036, 0.041, 0.095, and 1.04 μM, respectively. IDO/Tubulin-IN-2 is valuable for research applications in cancer biology, particularly in elucidating mechanisms of tumorigenesis and therapeutic resistance. -
Tubulin Polymerization Inhibitor
Tubulin polymerization-IN-61 is a potent tubulin polymerization inhibitor that disrupts microtubule dynamics, leading to the destruction of the microtubule skeleton. This compound effectively blocks the cell cycle at the G2/M phase, inducing apoptosis and inhibiting cancer cell migration and colony formation. In preclinical studies, Tubulin polymerization-IN-61 demonstrates significant antitumor activity in the 4T1 xenograft model, highlighting its potential for cancer research and therapeutic applications. -
Tubulin Polymerization Inhibitor
Tubulin Inhibitor 33 is a tubulin polymerization inhibitor that disrupts microtubule assembly in a dose-dependent manner, with an IC50 of 9.05 μM. This compound exhibits significant antitumor activity by promoting apoptosis in cancer cells. Tubulin Inhibitor 33 is a valuable reagent for research focusing on cancer biology and the mechanisms of tumorigenesis. -
Tubulin/MMP Inhibitor
Tubulin/MMP-IN-2 is a dual inhibitor targeting both tubulin and matrix metalloproteinases (MMPs). It effectively inhibits tubulin polymerization, leading to induced apoptosis in cancer cells. Additionally, Tubulin/MMP-IN-2 demonstrates inhibitory activity against MMP-2, MMP-3, and MMP-9, with IC50 values of 24.95 μM, 31.60 μM, and 22.37 μM, respectively. This compound is valuable for research focused on cancer biology and therapeutic development. -
Microtubule/Tubulin Inhibitor
Maytansine is a highly potent microtubule-targeting agent that disrupts microtubule dynamics, leading to mitotic arrest and apoptosis in tumor cells. It exerts cytotoxic effects at subnanomolar concentrations and serves as the cytotoxic payload component in several antibody–drug conjugates (ADCs) used for targeted cancer therapy. -
Microtubule/Tubulin Inhibitor
EAPB 02303 is a microtubule-disrupting agent that inhibits microtubule dynamics, leading to mitotic arrest and impaired spindle assembly. This disruption induces apoptosis and contributes to its antitumor activity. EAPB 02303 also demonstrates potent synergistic effects with Paclitaxel at lower concentrations, enhancing its potential in combination cancer therapies. -
CBSI inhibitor
MY-673 is a colchicine binding site inhibitor (CBSI) that disrupts microtubule dynamics by inhibiting tubulin polymerization. In addition to its antimitotic effects, MY-673 suppresses the ERK signaling pathway, which leads to modulation of SMAD4 protein expression within the TGF-β/SMAD signaling axis. These combined actions result in potent inhibition of cancer cell proliferation and migration, and the induction of apoptosis, both in vitro and in vivo. MY-673 holds promise as a therapeutic candidate for targeting cancers driven by aberrant microtubule dynamics and dysregulated TGF-β/ERK signaling. -
HDAC6 inhibitor
T-518 is an orally active, selective histone deacetylase 6 (HDAC6) inhibitor with an IC₅₀ of 36 nM for human HDAC6. It is capable of crossing the blood–brain barrier, making it suitable for central nervous system applications. T-518 is particularly useful in tauopathy research, where HDAC6 inhibition may modulate tau pathology and neurodegenerative processes. -
Tubulin/AKT1 Inhibitor
Tubulin/AKT1-IN-1 is an inhibitor of tubulin polymerization and AKT pathway activation. This compound demonstrates significant inhibition of proliferation and metastasis in H1975 cells, along with a modest induction of apoptosis. Tubulin/AKT1-IN-1 is particularly relevant for research in non-small cell lung cancer (NSCLC), providing a valuable tool for studying therapeutic strategies against this malignancy. -
Tubulin Inhibitor
Tubulin-IN-55 is a potent tubulin inhibitor that disrupts the PI3K/Akt signaling pathway in cancer cells. This compound exhibits broad-spectrum anti-proliferative effects against various tumor cell lines, including HeLa, HCT116, 4T1, A549, H1299, and MDA-MB231. Tubulin-IN-55 induces G2/M phase arrest and promotes apoptosis, while also inhibiting tumor cell migration and invasion. In vivo studies demonstrate significant antitumor efficacy in orthotopic autologous transplantation models, making Tubulin-IN-55 a valuable tool for cancer research. -
Tubulin/CDC5L Inhibitor
Tubulin/CDC5L-IN-1 is a dual inhibitor targeting both tubulin and CDC5L. It inhibits cancer cell proliferation and induces G2/M phase arrest, facilitating apoptosis and reactive oxygen species (ROS) production in affected cells. Additionally, Tubulin/CDC5L-IN-1 demonstrates antiangiogenic properties, making it a valuable tool for cancer research, particularly in studies related to colon carcinoma. -
Microtubule Inhibitor
Microtubule Inhibitor 2 acts as a selective microtubule disruptor, inducing cell death via ferroptosis. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. Its oral bioavailability enhances its utility in in vivo studies, facilitating investigations into the mechanisms underlying microtubule-targeted therapies. -
Microtubule Inhibitor
Microtubule Inhibitor 8 (MP-HJ-1b) targets microtubule dynamics, acting as a potent disruptor of microtubule processing. This compound initiates cell death through the ferroptosis pathway and exhibits significant anti-tumor activity. It serves as an essential tool for research in cancer biology and therapeutic development focused on targeting microtubules. -
Tubulin Inhibitor
Tubulin Inhibitor 30 is a potent tubulin polymerization inhibitor, exhibiting an IC50 of 0.52 μM. This compound disrupts microtubule dynamics, leading to the induction of ferroptosis in various cell types. It serves as a valuable tool for research on cancer biology and therapeutic applications targeting the cytoskeletal network. -
Microtubule Inhibitor
Polatuzumab vedotin is an antibody-drug conjugate that targets CD79b and functions primarily as a microtubule inhibitor. This compound consists of a humanized anti-CD79b IgG1 monoclonal antibody conjugated to monomethyl auristatin E (MMAE), a potent agent that disrupts microtubule dynamics. Its unique mechanism makes Polatuzumab vedotin a valuable tool for studying large B-cell lymphomas (LBCL) and exploring therapeutic approaches in related malignancies. Researchers can leverage its targeted delivery system for enhanced therapeutic efficacy in the context of cancer research. -
Microtubule Disassembly Inhibitor
10-Acetyl docetaxel is a microtubule disassembly inhibitor known for its antimitotic activity. As an analog of Docetaxel, this compound effectively disrupts microtubule dynamics, making it a valuable reagent in cancer research. Its mechanism of action can be leveraged to study cellular processes related to mitosis and the development of anticancer therapies. -
Microtubule/Tubulin Inhibitor
DM4-SMe is a potent tubulin inhibitor, primarily targeting microtubules to disrupt cytoskeletal functions. As a metabolite of antibody-maytansinoid conjugates, it serves as a cytotoxic component in antibody-drug conjugates. DM4-SMe exhibits significant biological activity, demonstrating an IC50 of 0.026 nM against KB cells. Additionally, this highly toxic metabolite undergoes oxidation and detoxification by human liver microsomes, which may influence its pharmacokinetic profile in biological systems. -
Tubulin Polymerization Inhibitor
Fmoc-MMAF-OMe is a tubulin polymerization inhibitor that features an Fmoc protecting group. The active component, MMAF, serves as a cytotoxic agent in antibody-drug conjugates (ADCs), making it critical for cancer research. Its ability to disrupt microtubule dynamics positions Fmoc-MMAF-OMe as a valuable tool for studying various cancer pathways and evaluating potential therapeutic strategies. -
Microtubule Inhibitor
S-methyl DM1 is a thiomethyl derivative of Maytansine and functions as a microtubule inhibitor. It binds to tubulin with a dissociation constant (Kd) of 0.93 μM, effectively inhibiting microtubule polymerization and potently suppressing microtubule dynamic instability. Due to its mechanism of action, S-methyl DM1 exhibits significant anticancer properties, making it a valuable reagent for research in cancer biology and therapeutics. -
Microtubule/Tubulin Inhibitor
DM3-SMe is a maytansine derivative that acts as a potent tubulin inhibitor. This compound exhibits remarkable cytotoxic activity in vitro, with an IC50 of 0.0011 nM, making it suitable for various research applications, particularly in the development of antibody-drug conjugates (ADCs). DM3-SMe can be conjugated to antibodies via disulfide or stable thioether bonds, enhancing the targeted delivery of cytotoxic agents in cancer therapy research. -
Microtubule/Tubulin Inhibitor
Tubulysin IM-2 is a potent microtubule and tubulin inhibitor that disrupts microtubule polymerization, leading to cell cycle arrest and apoptosis in tumor cells. This compound serves as a valuable component in antibody-drug conjugates (ADCs) by imparting cytotoxic effects and enhancing therapeutic efficacy. It is particularly useful in cancer research where targeting microtubule dynamics is crucial for investigating tumor progression and treatment responses. -
Microtubule/Tubulin Inhibitor
Bis-ANS dipotassium is a fluorescent probe that targets tubulin, acting as a microtubule inhibitor. It exhibits a binding affinity with tubulin characterized by a Kd of 2 μM. This compound serves as a potent biphasic modulator of protein liquid-liquid phase separation (LLPS), promoting LLPS at low concentrations while suppressing it at elevated concentrations. Its unique properties make it valuable for studying microtubule dynamics and phase separation mechanisms in cellular processes. -
Tubulin Polymerisation Inhibitor
Tubulin Polymerization-IN-38 is a tubulin polymerization inhibitor that disrupts microtubule dynamics, leading to enhanced apoptosis in cancer cells. As an analogue of Tubulysin, it demonstrates powerful anticancer activity and serves a pivotal role in research applications focusing on cancer treatment and drug discovery. This compound can also be utilized as an antibody-drug conjugate (ADC) cytotoxin, facilitating the synthesis of targeted therapies for oncology research. -
Tubulin Polymerization Inhibitor
Tubulysin D is a potent tubulin polymerization inhibitor that disrupts microtubule dynamics. This highly cytotoxic compound, derived from the myxobacteria Archangium geophyra and Angiococcus disciformis, exhibits significant activity against mammalian cells, including those with multidrug resistance, with IC50 values in the low nanomolar range. By preventing microtubule assembly, Tubulysin D induces cell cycle arrest and apoptosis, making it a valuable tool for cancer research and studies on microtubule-targeting therapies. -
Tubulin Inhibitor
Bi-Mc-VC-PAB-MMAE is a drug-linker conjugate that targets tubulin through a potent microtubule destabilizer, MMAE. The compound combines the ADC linker Bi-Mc-Val-Cit-PAB with MMAE to inhibit microtubule polymerization, effectively disrupting cellular mitotic processes. This reagent is primarily used in antibody-drug conjugate (ADC) research for its potential applications in targeted cancer therapies.
